Phase II Evaluation of the Efficacy of TXA127 (Angiotensin 1-7) to Reduce Acute Graft-vs.-Host Disease in Adults Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Angiotensin-1-7 (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors Tarix Pharmaceuticals
- 18 Dec 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 28 Jun 2013 New trial record